Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)

Main Article Content

Eric Simpson
Department of Dermatology, Oregon Health & Science University, Portland, OR, USA

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

Emma Guttman-Yassky
Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Margitta Worm
Division of Allergy and Immunology, Department of Dermatology, Venereology, and Allergy, Charit? ? Universit?tsmedizin Berlin, Berlin, Germany

Charles Lynde
Lynde Dermatology, Probity Medical Research, Markham, ON, Canada and Department of Medicine University of Toronto, Toronto, ON, Canada

Hidehisa Saeki
Department of Dermatology, Nippon Medical School, Tokyo, Japan

Yves Poulin
Laval University and Centre Dermatologique du Qu?bec M?tropolitain and Centre de Recherche Dermatologique du Qu?bec M?tropolitain, Qu?bec, QC, Canada

Andreas Wollenberg
Klinikum der Universit?t Mu?nchen, Klinik und Poliklinik fu?r Dermatologie und Allergologie, Munich, Germany

Keywords

Atopic Dermatitis, Biologic, Safety, Efficacy, Tralokinumab

Abstract

Abstract not available.

References

1. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

2. Boguniewicz M, Leung DY. Immunol Rev 2011; 242: 233–246.

3. Guttman-Yassky E et al. Semin Cutan Med Surg 2017; 36: 100–103.

4. Szegedi K et al. J Eur Acad Dermatol Venereol 2015; 29: 2136–2144.

5. Popovic B et al. J Mol Biol 2017; 429: 208–219.

6. Furue K et al. Immunology 2019; 158: 281–286.

7. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489. 8. Bieber T. Allergy 2020; 75: 54–62.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.96

Article Details

How to Cite
[1]
Simpson, E., Blauvelt, A., Guttman-Yassky, E., Worm, M., Lynde, C., Saeki, H., Poulin, Y. and Wollenberg, A. 2020. Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2). SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s96. DOI:https://doi.org/10.25251/skin.4.supp.96.
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 6 7 8 9 10 11 12 13 14 > >>